Mark Hanson

Mark Hanson is a senior managing director in Evercore’s strategic advisory practice.

Mr. Hanson has more than 30 years of experience advising companies across the healthcare sector, with a focus on technology, services, and life sciences tools & diagnostics.

Recent transactions include advising ArisGlobal on its sale to Dassault Systèmes; Clario on its sale to Thermo Fisher; Becton Dickinson on the sale of its biosciences and diagnostics solutions business to Waters; Dotmatics on its sale to Siemens; HealthEdge on its sale to Bain; QGenda on its sale to Hearst; GE HealthCare on its acquisition of Intelerad and separation from GE; Athenahealth on its sale to H&F and Bain; Vocera on its sale to Stryker; Parexel on its sale to EQT and GSAM; Nuance on its sale to Microsoft; Kelsey-Seybold on its sale to Optum; Centene on numerous acquisitions and divestitures, including WellCare; and Aetna on its sale to CVS Health.

For the 10 years prior to joining Evercore in 2014, Mr. Hanson was a managing director at Barclays and Lehman Brothers, leading the life sciences tools and healthcare services team. He began his career at Merrill Lynch.

He earned a B.A. in economics and mathematics from St. Olaf College and an MBA from Dartmouth’s Tuck School of Business.